A Pilot & Feasibility Study of the Imaging Potential of EC17 in Subjects Undergoing Surgery Presenting With Triple Negative Breast Cancer
Phase of Trial: Phase I
Latest Information Update: 22 Mar 2018
Price : $35 *
At a glance
- Drugs Folate-fluorescein isothiocyanate conjugate (Primary)
- Indications Breast cancer; Male breast cancer
- Focus Diagnostic use
- 16 Mar 2018 Status changed from active, no longer recruiting to completed.
- 11 Jun 2017 Status changed from recruiting to active, no longer recruiting.
- 04 Dec 2015 Planned End Date changed from 1 Dec 2015 to 1 Feb 2018, according to ClinicalTrials.gov record.